DCLK1 drives malignant progression and chemoresistance of bladder cancer by deubiquitinating HDAC6

膀胱癌 癌症研究 脱氮酶 生物 顺铂 恶性肿瘤 HDAC6型 免疫疗法 间质细胞 免疫检查点 下调和上调 免疫系统 癌症 肿瘤进展 平方毫米 髓系白血病 肺癌 癌变 化疗 医学 长非编码RNA 基因敲除 细胞 尿路上皮 免疫学 转移 质量细胞仪 癌细胞 膀胱
作者
Ashuai Du,Yuzheng Zhou,Xinpei Deng,Dongbo Yuan,Kai Li,Yuanyuan Luo,Songsong Tan,Xuchao Dai,Bo Yu,Kehua Jiang,Xingliang Tan,Jianguo Zhu
出处
期刊:Molecular Cancer [BioMed Central]
卷期号:25 (1)
标识
DOI:10.1186/s12943-025-02560-y
摘要

Bladder cancer (BC) is the most common malignancy of the urinary system, with rising incidence and mortality. Advanced BC frequently recurs or metastasizes and is often refractory to curative surgical intervention. Although cisplatin-based chemotherapy remains the standard first-line treatment, its clinical efficacy is frequently compromised by the development of drug resistance. Elucidating the molecular mechanisms underlying chemoresistance and metastasis is therefore critical for improving therapeutic strategies. Single-cell RNA sequencing (scRNA-seq) was conducted to assess intratumoral heterogeneity and identify expression programs associated with bladder cancer progression. DCLK1 emerged as a key cancer-related hub gene. Its role in metastasis, cisplatin resistance, and immune evasion was evaluated using sphere formation, CCK-8, Transwell, CFSE staining, and flow cytometry assays. The interaction between DCLK1, USP10, and HDAC6 was confirmed through RNA pull-down, co-immunoprecipitation, mass spectrometry, cell localization, and molecular docking. Finally, the therapeutic potential of DCLK1, cisplatin, and ACY-1215 (an HDAC6 inhibitor) was tested in vivo. We identified multiple cell types, including cancer cells, lymphocytes, myeloid cells, fibroblasts, and other stromal components. In cancer cells, six biologically relevant expression programs were revealed. Among key cancer-related genes, DCLK1 was notably enriched and promoted bladder cancer metastasis, cisplatin resistance, and stemness. Mechanistically, DCLK1 activated the Notch pathway to upregulate PD-L1, suppress CD8⁺ T cell activity, and promote immune evasion. It also facilitated USP10-HDAC6 interaction, removing K48-linked ubiquitin at Lys116 to prevent HDAC6 degradation. Importantly, HDAC6 depletion abrogated the oncogenic effects of DCLK1, whereas inhibition of DCLK1 suppressed tumor progression and enhanced the antitumor efficacy of combined cisplatin and ACY-1215 treatment. DCLK1 is a critical driver of bladder cancer progression, chemoresistance, and immune escape. Single-cell analysis and functional assays revealed that DCLK1 enhances metastasis and stemness by activating the Notch/PD-L1 axis and stabilizing HDAC6 through USP10 interaction. Targeting DCLK1, alone or in combination with cisplatin and HDAC6 inhibition, represents a promising therapeutic strategy for advanced bladder cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
认真的安寒完成签到,获得积分10
刚刚
RUSH关注了科研通微信公众号
刚刚
什么我才是大萌萌完成签到,获得积分0
刚刚
1秒前
trouble虫虫发布了新的文献求助10
2秒前
LIU发布了新的文献求助30
3秒前
成就完成签到,获得积分10
3秒前
Ml完成签到,获得积分10
5秒前
星星轨迹发布了新的文献求助10
5秒前
5秒前
爆米花的应助被倒数第二采纳,获得30
6秒前
苹果桐发布了新的文献求助10
6秒前
6秒前
6秒前
6秒前
宁静的夏天给hhh的求助进行了留言
7秒前
红雨灰衣发布了新的文献求助10
7秒前
万能图书馆的应助被榴莲采纳,获得10
8秒前
实验顺顺顺完成签到,获得积分10
8秒前
9秒前
10秒前
张航源完成签到,获得积分10
10秒前
深情安青的应助被tangpc采纳,获得100
10秒前
10秒前
Louis完成签到,获得积分10
10秒前
Orange的应助被小y同学采纳,获得10
11秒前
11秒前
奔跑的应助被Nnnnnn采纳,获得10
11秒前
11秒前
12秒前
13秒前
13秒前
14秒前
qin完成签到,获得积分10
14秒前
幸福完成签到,获得积分10
15秒前
郑瑞完成签到 ,获得积分10
16秒前
叫滚滚发布了新的文献求助10
17秒前
蓝天发布了新的文献求助10
18秒前
lin_jiayi发布了新的文献求助10
18秒前
顺心的凝海完成签到 ,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183694
求助须知:如何正确求助?哪些是违规求助? 9572963
关于积分的说明 21828306
捐赠科研通 7780864
什么是DOI,文献DOI怎么找? 3434057
关于科研通互助平台的介绍 2558257
邀请新用户注册赠送积分活动 2480541